DocWire News Editors

DocwireNews

Recent advancements have found a novel approach to treating Acute Myeloid Leukemia (AML), the most common form of leukemia. These findings come from a group of researchers at the Vetmeduni Vienna and the Ludwig Boltzmann Institute for Cancer Research, who found that activity of the mutated oncogene C/EBP&alpha; is dependent on a specific epigenetic factor. This factor, MLL1 histone methyltransferase complex, was found to be linked to death of AML cells with C/EBP&alpha; mutations.According to the study results, published in Leukemia, an interaction between the mutated protein and this epigenetic regulator leads to vulnerability of these AML cells. If the MLL1 complex was inhibited, the researchers noted that the AML cells went through cell death. By targeting MLL1 with inhibitory drugs, the block in blood cell maturation caused by the cancer could be potentially alleviated in AML patients.The transcription factor CCAAT/enhancer binding protein alpha C/EBP&alpha; is an important regulatory factor of blood development that controls critical functions in blood maturation. In 10-15% of AML patients, however, the C/EBP&alpha; gene contains mutations that prevent proper formation of the correct protein.<a href="https://proddocwire.wpengine.com/docwire-pick/home-page-picks/study-mutant-genes-severe-breast-cancer/">READ MORE:&nbsp;Study Finds Mutant Genes Linked to Severe Breast Cancer</a>&ldquo;In AML patients, most mutations occur in the N-terminal part of the CEBPA gene. This leads to the production of a shortened C/EBP&alpha; protein, the isoform p30, which is responsible for keeping cells in an immature state and can thus trigger leukemia,&rdquo; said study author Luisa Schmidt.The over-produced C/EBP&alpha; p30 protein variant uses epigenetic mechanisms to control gene expression in leukemia cells. This specific protein isoform has been associated with genetic expression patterns seen in leukemia cells. The variant binds promoters of oncogenes and recruits chromatin-modifying complexes such as histone methyltransferases. The MLL1 complex is one of these specific complexes required for transcriptional activation and is critical for hematopoietic stem cell maintenance as well.&ldquo;Using a combination of biochemical, genetic and pharmacological approaches, we have now been able to show that the MLL1 histone methyltransferase complex is a critical vulnerability in AML with CEBPA mutations,&rdquo; said Schmidt.Studies of protein-DNA interactions have shown that the C/EBP&alpha; p30 isoform binding pattern strongly overlaps with MLL1&rsquo;s, suggesting that the two factors interact with one another. This hypothesis was supported in additional experimenting.<a href="https://proddocwire.wpengine.com/docwire-pick/hem-onc-picks/u-s-cancer-mortality-25-year-decline/">READ MORE:&nbsp;U.S. Cancer-Related Mortality Rate Continues 25-Year Decline</a>Targeting the MLL1 complex with CRISPR/Cas9 mutagenesis further demonstrated C/EBP&alpha;-mutated AML cell growth being dependent on correct functioning of the MLL1 complex. Such AML cells were observed to be highly sensitive to pharmacological inhibition of MLL1 complexes. Inhibiting the complex was associated with impaired cell proliferation and death of the mutated AML cells. This treatment was also associated with reversal of the differentiation block of cancer cells, restoring normal blood cell maturation.&ldquo;The result that C/EBP&alpha; p30 requires a functional MLL1 complex to control oncogenic gene expression programs reveals a high sensitivity of CEBPA- mutated AML to the inhibition of the MLL1 complex function,&rdquo; said study leader Florian Grebien. &ldquo;These results broaden our understanding of CEBPA-mutated AML and identify the MLL1 complex as a potential therapeutic target for this disease.&rdquo;<blockquote class="twitter-tweet" data-lang="en">
<a href="https://twitter.com/hashtag/AML?src=hash&amp;ref_src=twsrc%5Etfw">#AML</a> New therapy for aggressive blood cancer discovered <a href="https://t.co/X8HviiB2Sw">https://t.co/X8HviiB2Sw</a>
&mdash; Concentric Health Experience (@ConcentricHX) <a href="https://twitter.com/ConcentricHX/status/1095733830739206145?ref_src=twsrc%5Etfw">February 13, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Source: <a href="https://www.sciencedaily.com/releases/2019/02/190213091651.htm">Science Daily</a>

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Seldin Award Winner Advocates Online Education

Latest News

Study Identifies New Treatment Option for Severe Leukemia Patients

Future of Medicine

Recent advancements have found a novel approach to treating Acute Myeloid Leukemia (AML), the most common form of leukemia. These findings come from a group of researchers at ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe